John MaherBA, MBBCh, BAO(Hons), MRCPI, MRCP(UK), MSc, FRCPath
John Maher was Clinically active Physician Immunologist with a demonstrated history of working in the research industry. He was First to engineer and develop CD28-based second-generation CAR technology in human T-cells. He has Twenty years of experience in pre-clinical and clinical development of CAR T cell immunotherapy, other forms of immunotherapy and immunopathology. Chief investigator of a CAR-T Phase I clinical trial in refractory head and neck cancer. He Holds FRCPath in Immunology (by examination) from Royal College of Pathologists and registered on the General Medical Council specialist register of Clinical Immunologists.